Ann: Compelling Preclinical Breast Cancer Results, page-42

This is a complex table since the dose used in patients is very different for Bisantrene and doxorubicin. You can give a patient 5x more Bisantrene than doxorubicin so if they have equivalent sensitivities at a fixed concentration this means anything above 0.2 actually shows that Bisantrene is better at killing the cancer cells than doxorubicin.

The real value of this table is the comparison between the different resistant cell lines (all the MCF sub-lines). This is the major news from this report - in simple terms it appears that unlike doxorubicin and epirubicin, resistance to other breast cancer drugs does not result in resistance to Bisantrene.

What does this mean? It basically means that Bisantrene may be a very good treatment option for late stage breast cancer patients that have grown resistant to all the existing treatments. This data supports running a Phase II clinical trial in late stage metastatic patients purely from a efficacy perspective and not just a safety perspective. It is much easier to get a drug approved that shows better efficacy than one that just shows better safety.

If all of this is still too complex, the bottom line is these results have derisked Pillar 2.